Allergan Aesthetics Unveils Global Consumer Research on Aesthetic Trends
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ABBV?
Source: Newsfilter
- Changing Consumer Expectations: A global survey of over 12,000 consumers reveals that 62% find multiple aesthetic treatments appealing, and 59% are likely to adopt a structured multi-treatment approach, indicating a growing demand for personalized and integrated treatment plans that enhance Allergan Aesthetics' market competitiveness.
- Evolution of AA Signature™: The AA Signature™ framework has evolved over the past year to include new elevated looks and enhanced product integration, with 74% of respondents intending to improve facial skin quality in the next 12 months, reflecting the company's agility in adapting to market trends and consumer needs.
- AMWC 2026 Highlights: At the upcoming AMWC 2026, Allergan Aesthetics will launch the new report
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 219.760
Low
223.00
Averages
252.00
High
289.00
Current: 219.760
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Allergan Aesthetics Unveils Global Consumer Research on Aesthetic Trends
- Changing Consumer Expectations: A global survey of over 12,000 consumers reveals that 62% find multiple aesthetic treatments appealing, and 59% are likely to adopt a structured multi-treatment approach, indicating a growing demand for personalized and integrated treatment plans that enhance Allergan Aesthetics' market competitiveness.
- Evolution of AA Signature™: The AA Signature™ framework has evolved over the past year to include new elevated looks and enhanced product integration, with 74% of respondents intending to improve facial skin quality in the next 12 months, reflecting the company's agility in adapting to market trends and consumer needs.
- AMWC 2026 Highlights: At the upcoming AMWC 2026, Allergan Aesthetics will launch the new report
See More
Allergan Aesthetics Unveils New Research Highlighting Evolving Patient Expectations in Aesthetics
- Consumer Research Findings: Allergan Aesthetics' global consumer research reveals that 62% of respondents find multiple aesthetic treatments appealing, and 59% are likely to adopt a structured multi-treatment approach, indicating a growing demand for personalized and integrated treatment solutions that could enhance the company's innovation and market share in aesthetics.
- Evolution of AA Signature™ Framework: The AA Signature™ framework has evolved over the past year to include new elevated looks and expanded indications, reflecting changing patient expectations and aiming to meet market demands through personalized multimodal treatment plans, thereby strengthening brand competitiveness.
- AMWC 2026 Conference Presentation: At the upcoming AMWC 2026 conference, Allergan Aesthetics will launch the new report
See More
Johnson & Johnson's Icotyde Receives FDA Approval
- FDA Approval: Johnson & Johnson's oral medication Icotyde has received FDA approval, becoming the first oral option for treating moderate to severe plaque psoriasis, expected to serve as the first-line systemic treatment between topical and injectable therapies.
- Significant Market Potential: J&J anticipates that Icotyde could exceed $5 billion in annual sales once approved for other autoimmune conditions, highlighting its substantial potential in the competitive psoriasis treatment market.
- Increased Patient Acceptance: The oral formulation of Icotyde is likely to appeal to approximately 75% of the 8 million U.S. psoriasis patients who do not transition from topical treatments to injections due to needle phobia, potentially enhancing patient adherence to treatment.
- Changing Competitive Landscape: Icotyde targets the same IL-23 receptor as J&J's Tremfya and AbbVie's Skyrizi, offering a relatively simple and safe treatment option that could alter the competitive dynamics in psoriasis treatment.
See More
Johnson & Johnson's Icotyde Approved by FDA for Psoriasis
- FDA Approval: Johnson & Johnson's once-daily oral medication Icotyde has received FDA approval, marking a significant breakthrough as the first oral option for treating moderate to severe plaque psoriasis.
- Significant Market Potential: J&J anticipates peak annual sales of Icotyde exceeding $5 billion, showcasing its strong competitive edge in the treatment market, particularly against injectable drugs like Tremfya and Skyrizi.
- Increased Patient Acceptance: Targeting the IL-23 receptor, Icotyde offers a non-injection treatment option, expected to attract 75% of the 8 million U.S. psoriasis patients who typically avoid injections, significantly enhancing patient treatment experiences.
- Future Expansion Plans: J&J is also testing Icotyde for other autoimmune conditions such as psoriatic arthritis and Crohn's disease, further broadening its market applications and strengthening the company's strategic position in the biopharmaceutical sector.
See More
AbbVie Faces New Competition as Skyrizi Sales Outlook Remains Positive
- Increased Competition: AbbVie (ABBV) shares fell approximately 4% on Wednesday as BNP Paribas analysts highlighted that the FDA approval of Icotyde, a pill developed by Johnson & Johnson (JNJ) and Protagonist Therapeutics (PRGX), could pose a competitive threat to AbbVie's immunology blockbuster Skyrizi.
- Market Expansion Potential: Despite the potential competition from Icotyde, analysts believe that Skyrizi remains well-positioned in the plaque psoriasis market due to its strong efficacy and compliance advantages of its injectable form, projecting a 23% year-over-year sales increase for Skyrizi in FY26E.
- Increased Market Penetration: Analysts noted that the introduction of Icotyde could help expand the market, with current penetration rates at 30-40%, suggesting that Skyrizi still has room for growth, with a projected CAGR of 14% from FY25-28E.
- Future Competitive Risks: Ongoing studies for Icotyde in other inflammatory disorders, such as psoriatic arthritis, could represent additional competition for Skyrizi, although AbbVie’s strong market position suggests that future sales growth remains a critical driver for the company.
See More
IVW Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: IVW's 52-week low is $79.31 and high is $126.605, with the current trading price at $118.64, indicating volatility near the high point that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in outstanding shares for ETFs highlights significant inflows (new units created) or outflows (old units destroyed), which can affect the performance of individual stocks held within the ETFs.
See More
Allergan Aesthetics Unveils Global Consumer Research on Aesthetic Trends
- Changing Consumer Expectations: A global survey of over 12,000 consumers reveals that 62% find multiple aesthetic treatments appealing, and 59% are likely to adopt a structured multi-treatment approach, indicating a growing demand for personalized and integrated treatment plans that enhance Allergan Aesthetics' market competitiveness.
- Evolution of AA Signature™: The AA Signature™ framework has evolved over the past year to include new elevated looks and enhanced product integration, with 74% of respondents intending to improve facial skin quality in the next 12 months, reflecting the company's agility in adapting to market trends and consumer needs.
- AMWC 2026 Highlights: At the upcoming AMWC 2026, Allergan Aesthetics will launch the new report
See More
Allergan Aesthetics Unveils New Research Highlighting Evolving Patient Expectations in Aesthetics
- Consumer Research Findings: Allergan Aesthetics' global consumer research reveals that 62% of respondents find multiple aesthetic treatments appealing, and 59% are likely to adopt a structured multi-treatment approach, indicating a growing demand for personalized and integrated treatment solutions that could enhance the company's innovation and market share in aesthetics.
- Evolution of AA Signature™ Framework: The AA Signature™ framework has evolved over the past year to include new elevated looks and expanded indications, reflecting changing patient expectations and aiming to meet market demands through personalized multimodal treatment plans, thereby strengthening brand competitiveness.
- AMWC 2026 Conference Presentation: At the upcoming AMWC 2026 conference, Allergan Aesthetics will launch the new report
See More
Johnson & Johnson's Icotyde Receives FDA Approval
- FDA Approval: Johnson & Johnson's oral medication Icotyde has received FDA approval, becoming the first oral option for treating moderate to severe plaque psoriasis, expected to serve as the first-line systemic treatment between topical and injectable therapies.
- Significant Market Potential: J&J anticipates that Icotyde could exceed $5 billion in annual sales once approved for other autoimmune conditions, highlighting its substantial potential in the competitive psoriasis treatment market.
- Increased Patient Acceptance: The oral formulation of Icotyde is likely to appeal to approximately 75% of the 8 million U.S. psoriasis patients who do not transition from topical treatments to injections due to needle phobia, potentially enhancing patient adherence to treatment.
- Changing Competitive Landscape: Icotyde targets the same IL-23 receptor as J&J's Tremfya and AbbVie's Skyrizi, offering a relatively simple and safe treatment option that could alter the competitive dynamics in psoriasis treatment.
See More
Johnson & Johnson's Icotyde Approved by FDA for Psoriasis
- FDA Approval: Johnson & Johnson's once-daily oral medication Icotyde has received FDA approval, marking a significant breakthrough as the first oral option for treating moderate to severe plaque psoriasis.
- Significant Market Potential: J&J anticipates peak annual sales of Icotyde exceeding $5 billion, showcasing its strong competitive edge in the treatment market, particularly against injectable drugs like Tremfya and Skyrizi.
- Increased Patient Acceptance: Targeting the IL-23 receptor, Icotyde offers a non-injection treatment option, expected to attract 75% of the 8 million U.S. psoriasis patients who typically avoid injections, significantly enhancing patient treatment experiences.
- Future Expansion Plans: J&J is also testing Icotyde for other autoimmune conditions such as psoriatic arthritis and Crohn's disease, further broadening its market applications and strengthening the company's strategic position in the biopharmaceutical sector.
See More
AbbVie Faces New Competition as Skyrizi Sales Outlook Remains Positive
- Increased Competition: AbbVie (ABBV) shares fell approximately 4% on Wednesday as BNP Paribas analysts highlighted that the FDA approval of Icotyde, a pill developed by Johnson & Johnson (JNJ) and Protagonist Therapeutics (PRGX), could pose a competitive threat to AbbVie's immunology blockbuster Skyrizi.
- Market Expansion Potential: Despite the potential competition from Icotyde, analysts believe that Skyrizi remains well-positioned in the plaque psoriasis market due to its strong efficacy and compliance advantages of its injectable form, projecting a 23% year-over-year sales increase for Skyrizi in FY26E.
- Increased Market Penetration: Analysts noted that the introduction of Icotyde could help expand the market, with current penetration rates at 30-40%, suggesting that Skyrizi still has room for growth, with a projected CAGR of 14% from FY25-28E.
- Future Competitive Risks: Ongoing studies for Icotyde in other inflammatory disorders, such as psoriatic arthritis, could represent additional competition for Skyrizi, although AbbVie’s strong market position suggests that future sales growth remains a critical driver for the company.
See More
IVW Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: IVW's 52-week low is $79.31 and high is $126.605, with the current trading price at $118.64, indicating volatility near the high point that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in outstanding shares for ETFs highlights significant inflows (new units created) or outflows (old units destroyed), which can affect the performance of individual stocks held within the ETFs.
See More
